McMaster University's Faculty of Health Sciences McMaster University Ottawa Hospital Children's Hospital of Eastern Ontario BioCanRx Ontario Institute for Cancer Research Fight Against Cancer Innovation Trust Fight Against Cancer Innovation Trust

Media Release — Cancer patients treated in world-first clinical trial of Canadian viral therapy

Date of release: July 10, 2015


For more information:

McMaster
University

Susan Emigh
Phone: 905-525-9140 ext. 22555
Email: emighs@mcmaster.ca

Ottawa
Hospital

Jenn Ganton
Phone: 613-614-5253
Email: iganton@ohri.ca

Children's Hospital
of Eastern Ontario

Adrienne Vienneau
Phone: 613-513-8437
Email: avienneau@cheo.on.ca


Ontario Institute for Cancer Research (OICR)

Christopher Needles
Phone: 416-673-8505
Email: Christopher.needles@oicr.on.ca

NCIC Clinical Trials Group

Heather Stanton
Phone: 613-533-6430
Email:hstanton@ctg.queensu.ca


* Note: To download files, right click on the link and select "Save As" or "Save Link As" or "Save target as" and save to your hard drive.

Embargoed until Friday, July 10, 2015 at 10:00 am EDT

Media Release

Photos (.jpg format)

Graphics (.jpg format)

A Novel Oncolytic Vaccine in the Fight against Cancer


Rhabdovirus

The Maraba virus used in this trial is a rhabdovirus and has this bullet-like shape. It was discovered in sandflies around the Maraba region of Brazil, and has been engineered to seek out cancer cells and do two things. As an oncolytic virus, it replicates inside the cancer cell and destroys it, while also triggering an immune response that recognizes the cancer as a threat.


Adenovirus

The adenovirus used in this trial is an engineered version of the common cold. It has been designed to initialize an immune response to a protein, MAGE-A3, expressed by many solid cancers.


Tumour / virus art from the Stojdl lab

Credit — somersault:1824, David Goodsell and Cronodon